Vemurafenib, a drug targeting BRAF mutation, induced positive results in treating metastatic thyroid cancer patients harboring the mutation.
Early-stage colon cancer patients who received adjuvant chemotherapy survived longer, a new retrospective study shows.
Researchers discovered that the patient’s body mass index is contributing to multiple myeloma growth and progression.
Patients undergoing chemotherapy experienced no nausea or vomiting after including olanzapine to their prophylactic drug combination, a phase 3 study reveals.
The inhibitor cabozantinib failed to induce significant benefit in prostate cancer patients, a phase 3 trial reveals.
A new analysis shows that cutting of sensory nerves during breast cancer surgery is connected with post-surgical chronic pain.
Childhood cancer survivors face the risk of an increased risk for a variety of health disorders, including endocrine abnormalities, a review showed.
A diagnosis of high cholesterol led to reduced mortality and improved survival in lung, breast, prostate and bowel cancer, a new researches reveals.
Physical activity improved subjective memory in breast cancer survivors, alleviating stress, a new study reports.
The use of cetuximab and radiation therapy compared with radiotherapy resulted in higher rate of laryngeal preservation in laryngeal cancer patients.
Breast cancer survivors who did acupressure over six weeks reduced fatigue, the most common long-term effects of breast cancer treatment.
EU regulator approved carfilzomib with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
The combination of cetuximab with FOLFOX statistically significantly improved patient outcomes in RAS wild-type metastatic colorectal cancer patients.
Patients with refractory liver cancer had a significant reduction in the risk of progression or death when treated with regorafenib, a phase 3 study shows.
A prostate cancer patient opted for active surveillance instead of prostatectomy. Changing urologists, he got advice to undergo a fusion MRI scan.
Post-operative treatment intensification with chemoradiotherapy and post-operative chemotherapy induced similar outcomes to gastric cancer patients.
Cisplatin treatment is to blame for the hearing loss of many testicular cancer survivors, researchers report.
Adding radiotherapy to androgen deprivation therapy in the treatment of metastatic prostate cancer patients prolonged survival more, an analysis reveals.
Breast cancer patients treated with aromatase inhibitors who continued smoking had a three times higher risk of recurrence of breast cancer, a study shows.
Removing with surgery a cancerous kidney helped metastatic kidney cancer patients live longer, a new study reveals.
Merck’s Keytruda immunotherapy prolonged survival without disease progression in advanced lung cancer patients, the results of a large trial show.
Breast conserving therapy was associated with a higher risk of metastasis compared to mastectomy in early breast cancer patients, younger than 45 years old.
The lack of regular exercise throughout adulthood is associated with an increased risk of developing and dying from ovarian cancer, a new analysis reveals.
Arimidex induced a clinical benefit for recurrent hormone receptor-positive endometrial cancer patients, as it improved their quality of life, a study finds.
Immunotherapy given directly after chemotherapy to ovarian cancer patients stimulated immune cells that can kill cancer cells, a new analysis reveals.
Treating early breast cancer patients with a shorter course of whole breast radiation induced the same outcomes as the longer course, a study reveals.
Advanced kidney cancer patients treated after disease progression with immunotherapy nivolumab survived longer, a new phase 3 study shows.
The existing cancer immunotherapy pembrolizumab induced positive outcomes to patients with undifferentiated pleomorphic sarcoma.
The immunotherapy nivolumab increased progression free survival with less adverse events in head and neck cancer patients.
Novartis's drug combination of Tafinlar and Mekinist increased progression-free survival in lung cancer patients almost up to 10 months, said the company.